Markets: Two to watch at the open
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
CSL Limited
CSL announced overnight the US Food and Drug Administration has approved a 50 mL vial size for Hizentra, available in the US from October. Hizentra essentially has a monopoly in the subcutaneous immunoglobulin market in the US and this positions them well to continue dominating the sector.
The benefits of a larger vial size include administration efficiency and simplifying care of patients who require infrequent large doses of the drug. Hizentra sales grew 27 per cent in the last reporting period, helping drive CSL immunoglobulin sales up 9 per cent for the full year.
CSL reached their all-time high of $69.00 on Tuesday and could push past this today.
Dart Energy
Dart Energy comes out of a trading halt this morning, with expectations it will announce a capital raising as they face a capital crunch.
Having to tap shareholders after looking to sell existing assets does not look good for Dart and should not be well received by shareholders.
Dart’s core operations have also recently come under pressure in Scotland by environmental groups angry about the potential extraction of coal seam gas in the region.
Shareholders have seen Dart shares plummet 48 per cent over the past twelve months.
Call 1300 880 160
Start a chat
Schedule a call
